Journal of Endocrinological Investigation

, Volume 26, Issue 4, pp 341–346 | Cite as

Insulin sensitivity and hyperprolactinemia

  • Alparslan Tuzcu
  • M. Bahceci
  • M. Dursun
  • C. Turgut
  • S. Bahceci
Original Article


It has been shown that prolactin (PRL) induces glucose intolerance, hyperinsulinemia and insulin resistance in several animal species. In women with microprolactinomas, the sensitivity to insulin is lower in hyperprolactinemia than in normoprolactinemia. Thirty non-obese women with hyperprolactinemia and 30 healthy non-obese women were included into the study. Age, body weight (bw), height, body mass index (BMI), waist circumference, hip circumference and waist to hip ratio of both patients with hyperprolactinemia and control sub-jects were not different. Mean serum prolactin level was higher in hyperprolactinemic patients than in control group (84.5±51.1 ng/ml and 13.8±5.3 ng/ml respectively, p<0.002). Mean HOMA-(%B) index of hyperprolactinemic patients was higher than in control subjects (121±49 and 84±38, respectively, p<0.02). Mean HOMA-(%S) index was lower in hyper-prolactinemic patients (56±39 and 105±55, respectively, p<0.006). Serum total testosterone, free testosterone, androstenedione, estradiol, cortisol, sex hormone binding globulin and DHEA-S levels in both hyperprolactinemic women and healthy subjects, statistically did not show any difference between the two groups. The present data indicate that hyperpro-lactinemia is associated with an insulin-resistant state. This resistant state may not be a result of obesity, androgenic hormones, and SHBG or pregnancy. It may be the result of serum free fatty acids (FFA) levels, decrement in the number of insulin receptors (by a down-regulation of insulin receptors) or post-binding defect in insulin action or more.


Hyperprolactinemia insulin resistance HOMA androgenic hormones and obesity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pijl H., Ohashi S., Matsuda M., et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000, 23: 1154–1161.PubMedCrossRefGoogle Scholar
  2. 2.
    Reis F.M., Reis A.M., Coimbra C.C. Effects of hyperpro-lactinemia on glucose tolerance and insulin release in male and female rats. J. Endocrinol. 1997, 153: 423–428.PubMedCrossRefGoogle Scholar
  3. 3.
    Matsuda M., Mori T. Effect of estrogen on hyperpro-lactinemia- induced glucose intolerance in SHN mice. Proc. Soc. Exp. Biol. Med. 1996, 212: 243–247.PubMedCrossRefGoogle Scholar
  4. 4.
    Serri O., Beauregard H., Rasio E., Hardy J. Decreased sensitivity to insulin in women with microprolactinomas. Fertil. Steril. 1986, 45: 572–574.PubMedGoogle Scholar
  5. 5.
    Gustafson A.B., Banasiak M.F., Kalkhoff R.K., Hagen T.C., Kim H.J. Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J. Clin. Endocrinol. Metab. 1980, 51: 242–246.PubMedCrossRefGoogle Scholar
  6. 6.
    Johnston D.G., Alberti K.G., Nattrass M., Burrin J.M., Blesa-Malpica G., Hall K., Hall R. Hyperinsulinaemia in hy-perprolactinaemic women. Clin. Endocrinol. (Oxf.) 1980 13: 361–368.CrossRefGoogle Scholar
  7. 7.
    Seki K., Nagata I. Levels of glucose and insulin during twenty-four hours in hyperprolactinemic women with pituitary microadenoma. Gynecol. Obstet. Invest. 1991, 31: 222–225.PubMedCrossRefGoogle Scholar
  8. 8.
    Schernthaner G., Prager R., Punzengruber C., Luger A. Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 1985, 28: 138–142.PubMedGoogle Scholar
  9. 9.
    Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment:insulin resitance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412–419.PubMedCrossRefGoogle Scholar
  10. 10.
    Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur. J. Clin. Invest. 2002, 32: 14–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Beck-Nielsen H. Insulin resistance: Organ manifestations and cellular mechanisms. Ugeskr. Laeger. 2002, 164: 2130–2135.PubMedGoogle Scholar
  12. 12.
    Hartman H.B., Hu X., Tyler K.X., Dalal C.K., Lazar M.A. Mechanisms regulating adipocyte expression of resistin. J. Biol. Chem. 2002, 277: 19754–19761.PubMedCrossRefGoogle Scholar
  13. 13.
    Foss M.C., Paula F.J., Paccola G.M., Piccinato C.E. Peripheral glucose metabolism in human hyperprolactinemia. Clin. Endocrinol. (Oxf.) 1995, 43: 721–726.CrossRefGoogle Scholar
  14. 14.
    Puavilai G., Drobny E.C., Domont L.A., Baumann G. Insulin receptors and insulin resistance in human pregnancy: evidence for a postreceptor defect in insulin action. J. Clin. Endocrinol. Metab. 1982, 54: 247–253.PubMedCrossRefGoogle Scholar
  15. 15.
    Aron D.C., Findling J.W., Tyrrell J.B. Hypothalamus and Pituitary. In: Greenspan F.S., Strewler G.J. (Eds.), Basic and clinical Endocrinology, ed. 5. Appleton and Lange, Connecticut, 1997, P. 109.Google Scholar
  16. 16.
    Ryan E.A., Enns L. Role of gestational hormones in the induction of insulin resistance. J. Clin. Endocrinol. Metab, 1988, 67: 341–347.PubMedCrossRefGoogle Scholar
  17. 17.
    Kim S.Y., Sung Y.A., Ko K.S., et al. Direct relationship between elevated free testosterone and insulin resistance in hyperprolactinemic women. Korean J. Intern. Med. 1993, 8: 8–14.PubMedGoogle Scholar
  18. 18.
    Falcone T., Meltzer S., Morris D. Effect of hyperpro-lactinemia on the androgen response to an oral glucose load. Fertil. Steril. 1992, 58: 1119–1122.PubMedGoogle Scholar
  19. 19.
    Cincotta A.H., Meier A.H., Cincotta Jr. M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert. Opin. Investig. Drugs. 1999, 8: 1683–1707.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2003

Authors and Affiliations

  • Alparslan Tuzcu
    • 1
  • M. Bahceci
    • 1
  • M. Dursun
    • 2
  • C. Turgut
    • 3
  • S. Bahceci
    • 4
  1. 1.Department of Endocrinology and MetabolismUniversity of Dicle, School of MedicineDiyarbakirTurkey
  2. 2.Department of GastroenterologyUniversity of Dicle, School of MedicineDiyarbakirTurkey
  3. 3.Department of BiochemistryUniversity of Dicle, School of MedicineDiyarbakirTurkey
  4. 4.Department of Histology and EmbryologyUniversity of Dicle, School of MedicineDiyarbakirTurkey

Personalised recommendations